For each disease examined, Decision Resources' Treatment Algorithms
Insight Series provides the following:
-- Qualitative diagnosis and referral patterns for the United States
based on thought leader input and guideline recommendations.
-- Quantitative treatment algorithms based on patient-level claims data
Product share (class and specific compound level) within each line
of therapy (1st, 2nd, 3rd line).
-- Practicing physician opinion on why specific drugs are chosen for
certain patient populations.
-- Discussion of key drug combinations (including add versus switch
patterns) by lines of therapy.
-- Progression of therapy from key 1st line products (e.g., initial
treatment with Lipitor to 2nd line, 3rd line; initial treatment with
Zocor to 2nd line, 3rd line).
-- Pathway to key therapies from previous therapies (e.g., how much
Avandamet use is preceded by metformin, Avandia, or both as single
-- Qualitative analysis of 2-year forecast incorporating practicing
physician sentiment towards upcoming launches, changes in
About Decision Resources
Decision Resources, Inc., (http://www.DecisionResources.com) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.
For more information,
|SOURCE Decision Resources|
Copyright©2008 PR Newswire.
All rights reserved